title: Tumor perfusion increases during hypofractionated short-course radiotherapy in rectal cancer: sequential perfusion-CT findings.
abstract: OBJECTIVE
  The purpose of this study was to investigate perfusion of rectal tumors and to determine early responses to short-course hypofractionated radiotherapy (RT).
  
  
  METHODS
  Twenty-three rectal cancer patients were included, which underwent perfusion-CT imaging before (pre-scan) and after treatment (post-scan). Contrast-enhancement was measured in tumor and muscle tissues and in the external iliac artery. Perfusion was quantified with three pharmacokinetic parameters: K(trans), v(e) and v(p). Perfusion differences between tumor and normal tissue and changes of the pharmacokinetic parameters between both scans were evaluated.
  
  
  RESULTS
  The median tumors K(trans) values increased significantly from the pre-scan (0.36+/-0.11 (min(-1))) to the post-scan (0.44+/-0.13 (min(-1))) (p<0.001). Also, histogram analysis showed a shift of tumor voxels from lower K(trans) values towards higher K(trans) values. Furthermore, the median K(trans) values were significantly higher for tumor than for muscle tissue on both the pre-scan (0.10+/-0.05 (min(-1)), p<0.001) and the post-scan (0.10+/-0.04 (min(-1)), p<0.001). In contrast, no differences between tumor and muscle tissues were found for v(e) and v(p). Also, no significant differences were observed for v(e) and v(p) between the two pCT-imaging time-points.
  
  
  CONCLUSIONS
  Hypofractionated radiotherapy of rectal cancer leads to an increased tumor perfusion as reflected by an elevated K(trans), possibly improving the bioavailability of cytotoxic agents in rectal tumors, often administered early after radiotherapy treatment.
authors.affiliation: Department of Radiation Oncology (MAASTRO), Maastricht University Medical Center (MUMC+), Maastricht, The Netherlands. marco.janssen@maastro.nl
authors.forename: Marco H M
authors.initials: MH
authors.lastname: Janssen
authors.forename: Hugo J W L
authors.initials: HJ
authors.lastname: Aerts
authors.forename: Roel G J
authors.initials: RG
authors.lastname: Kierkels
authors.forename: Walter H
authors.initials: WH
authors.lastname: Backes
authors.forename: Michel C
authors.initials: MC
authors.lastname: Ollers
authors.forename: Jeroen
authors.initials: J
authors.lastname: Buijsen
authors.forename: Philippe
authors.initials: P
authors.lastname: Lambin
authors.forename: Guido
authors.initials: G
authors.lastname: Lammering
mesh_terms: D003287:Contrast Media / Q000493:pharmacokinetics; D019583:Dose Fractionation, Radiation; D005260:Female; D019788:Fluorodeoxyglucose F18 / Q000493:pharmacokinetics; D006801:Humans; D021621:Imaging, Three-Dimensional; D007472:Iohexol / Q000031:analogs & derivatives / Q000493:pharmacokinetics; D008297:Male; D009367:Neoplasm Staging; D019275:Radiopharmaceuticals / Q000493:pharmacokinetics; D011879:Radiotherapy Dosage; D012004:Rectal Neoplasms / Q000098:blood supply* / Q000000981:diagnostic imaging* / Q000473:pathology / Q000532:radiotherapy*; D018709:Statistics, Nonparametric; D014055:Tomography, Emission-Computed; D014057:Tomography, X-Ray Computed / Q000379:methods*
chemical_list: D003287:Contrast Media; D019275:Radiopharmaceuticals; D019788:Fluorodeoxyglucose F18; C093233:iobitridol; D007472:Iohexol